These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29672836)

  • 1. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
    Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
    Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urachal cancer - current concepts of a rare cancer (German version)].
    Reis H; Szarvas T
    Pathologe; 2018 Dec; 39(Suppl 2):291-300. PubMed ID: 30470871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urachal cancer-current concepts of a rare cancer.
    Reis H; Szarvas T
    Pathologe; 2019 Jun; 40(Suppl 1):31-39. PubMed ID: 30895340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
    Kim H; Kim BH; Lee D; Shin E
    Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
    Riva G; Mian C; Luchini C; Girolami I; Ghimenton C; Cima L; Novelli L; Hanspeter E; Mazzoleni G; Schwienbacher C; Pycha S; D'Elia C; Trenti E; Pycha A; Martignoni G; Hes O; Eccher A; Nesi G; Brunelli M
    Virchows Arch; 2019 Jan; 474(1):13-20. PubMed ID: 30302546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status.
    Polom K; Das K; Marrelli D; Roviello G; Pascale V; Voglino C; Rho H; Tan P; Roviello F
    Pathol Oncol Res; 2019 Jan; 25(1):333-340. PubMed ID: 29116623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
    Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O
    Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations.
    Sirintrapun SJ; Ward M; Woo J; Cimic A
    Hum Pathol; 2014 Feb; 45(2):327-30. PubMed ID: 24355196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis.
    Ye ZL; Qiu MZ; Tang T; Wang F; Zhou YX; Lei MJ; Guan WL; He CY
    Cancer Med; 2020 Jan; 9(2):745-756. PubMed ID: 31782259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation.
    Hartman DJ; Binion DG; Regueiro MD; Miller C; Herbst C; Pai RK
    Inflamm Bowel Dis; 2018 Jul; 24(8):1780-1790. PubMed ID: 29788391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
    Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
    World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma.
    Cornejo KM; Cosar EF; Paner GP; Yang P; Tomaszewicz K; Meng X; Mehta V; Sirintrapun SJ; Barkan GA; Hutchinson L
    Int J Surg Pathol; 2020 Feb; 28(1):51-59. PubMed ID: 31496327
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of APC and PTEN Alterations in Urachal Cancer.
    Nagy N; Reis H; Hadaschik B; Niedworok C; Módos O; Szendrői A; Bíró K; Hager T; Herold T; Ablat J; Black PC; Okon K; Tolkach Y; Csizmarik A; Oláh C; Keresztes D; Bremmer F; Gaisa NT; Kriegsmann J; Kovalszky I; Kiss A; Tímár J; Szász MA; Rink M; Fisch M; Nyirády P; Szarvas T
    Pathol Oncol Res; 2020 Oct; 26(4):2773-2781. PubMed ID: 32754865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
    Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.
    Liu Y; Bischof E; Chen Z; Zhou J; Zhang B; Zhang D; Gao Y; Quan M
    Oncol Res; 2024; 32(9):1429-1438. PubMed ID: 39220126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.